|
Dr. Wahl’s scientific accomplishments have largely focused on the use of radiopharmaceuticals for the diagnosis and treatment of cancer. He and his collaborators have contributed over 200 peer-reviewed manuscripts to this area of work. He has performed both pre-clinical and clinical studies with radiolabeled monoclonal antibodies and is perhaps best known for his early work showing the value of monoclonal antibody fragments for imaging tumors and for his role in developing radioimmunotherapy of non-Hodgkins’ Lymphoma using anti CD-20 antibodies. The latter approach is particularly relevant to the ICMIC as this approach uses imaging to define precisely the dose of anti-cancer therapy to use in an individual patient. Dr. Wahl is also well known for his work on developing PET imaging of cancer, being substantially responsible for establishing that PET imaging with FDG is useful in a wide range of cancers. | 